Quest Diagnostics Incorporated (NYSE:DGX) Director Jeffrey M. Leiden sold 296 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $106.66, for a total transaction of $31,571.36. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at $639,960. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Quest Diagnostics Incorporated (NYSE:DGX) opened at 104.87 on Friday. Quest Diagnostics Incorporated has a one year low of $79.12 and a one year high of $112.96. The stock’s 50 day moving average is $108.23 and its 200-day moving average is $103.54. The company has a market cap of $14.30 billion, a PE ratio of 21.13 and a beta of 0.69.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.42 by $0.13. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 earnings per share. Equities research analysts expect that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Quest Diagnostics Incorporated (DGX) Director Jeffrey M. Leiden Sells 296 Shares” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.com-unik.info/2017/08/19/jeffrey-m-leiden-sells-296-shares-of-quest-diagnostics-incorporated-dgx-stock-updated.html.
DGX has been the topic of a number of recent research reports. Mizuho raised their price objective on shares of Quest Diagnostics from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, April 26th. Canaccord Genuity increased their target price on shares of Quest Diagnostics from $102.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, April 25th. Barclays PLC reiterated an “equal weight” rating and issued a $100.00 target price (up previously from $98.00) on shares of Quest Diagnostics in a report on Sunday, April 23rd. Deutsche Bank AG reiterated a “buy” rating and issued a $115.00 target price (up previously from $108.00) on shares of Quest Diagnostics in a report on Sunday, April 23rd. Finally, BidaskClub upgraded shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 29th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $109.62.
A number of institutional investors have recently bought and sold shares of DGX. Teachers Advisors LLC raised its position in Quest Diagnostics by 6.6% in the fourth quarter. Teachers Advisors LLC now owns 177,243 shares of the medical research company’s stock valued at $16,289,000 after buying an additional 11,003 shares during the period. Chevy Chase Trust Holdings Inc. raised its position in Quest Diagnostics by 2.3% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 118,823 shares of the medical research company’s stock valued at $11,667,000 after buying an additional 2,668 shares during the period. Creative Planning raised its position in Quest Diagnostics by 30.8% in the first quarter. Creative Planning now owns 4,159 shares of the medical research company’s stock valued at $408,000 after buying an additional 980 shares during the period. Gulf International Bank UK Ltd raised its position in Quest Diagnostics by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,053 shares of the medical research company’s stock valued at $4,423,000 after buying an additional 625 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Quest Diagnostics by 3.1% in the first quarter. Bank of Montreal Can now owns 292,342 shares of the medical research company’s stock valued at $28,705,000 after buying an additional 8,700 shares in the last quarter. Institutional investors own 90.06% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
What are top analysts saying about Quest Diagnostics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quest Diagnostics Incorporated and related companies.